David Risinger
Leerink Partners | Healthcare
David Risinger is an analyst from Leerink Partners specializing in the Healthcare sector. Ranked #1747 out of 4363 analysts, they have issued 9 stock ratings with a success rate of 72.76% and an average return of 19.29%.
With 9 ratings to date, David Risinger is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 72.76% and an average return of 19.29%, highlighting promising potential as their track record develops further.
Recent Ratings Analysis
HALO
HoldOct 14, 2025
Target
$70.00
Current
$66.88
Performance
0.35%
David Risinger rated HALO as Market Perform on Oct 14, 2025, setting a price target of 70. The Hold stance appears justified, as shares hovered around 66.88 with a 0.35% move.
VRTX
BuySep 25, 2025
Target
$456.00
Current
$408.61
Performance
7.00%
On Sep 25, 2025, VRTX was given a Outperform rating by David Risinger, with a target price of 456. The stock rallied 7.00% after the rating, narrowing the gap to the target of 456 and validating the bullish stance.
MTSR
HoldSep 24, 2025
Target
$57.00
Current
$52.86
Performance
0.69%
MTSR received a Market Perform rating from David Risinger on Sep 24, 2025, aiming for 57. Shares remained flat at 52.86, aligning with the neutral rating.
ROIV
BuySep 18, 2025
Target
$22.00
Current
$17.11
Performance
13.39%
On Sep 18, 2025, David Risinger published a Outperform outlook on ROIV, with a target of 22. Shares gained 13.39%, underscoring the accuracy of the bullish outlook toward 22.
REGN
BuyFeb 05, 2025
Target
$834.00
Current
$569.17
Performance
-20.59%
David Risinger on Feb 05, 2025 assigned REGN a Outperform rating, with a price target of 834. The call has struggled to gain traction, with shares losing 20.59%.
JNJ
BuyJan 23, 2025
Target
$169.00
Current
$192.12
Performance
31.01%
On Jan 23, 2025, David Risinger reaffirmed JNJ with a Outperform rating, targeting 169. The recommendation was supported by strong follow-through as the stock rose from 192.12 to 192.12.
ABBV
BuyNov 22, 2024
Target
$206.00
Current
$226.87
Performance
28.21%
ABBV was rated Outperform by David Risinger on Nov 22, 2024, with a price objective of 206. A bullish response from the market helped close the gap of -20.87 to the target.
TECX
BuyNov 11, 2024
Target
$69.00
Current
$17.65
Performance
-61.69%
On Nov 11, 2024, David Risinger initiated coverage on TECX with a Outperform rating and target of 69. The Buy call has yet to be validated as shares remain 51.35 away from the target.
ORKA
BuySep 17, 2024
Target
$44.00
Current
$26.56
Performance
0.34%
David Risinger issued a Outperform recommendation for ORKA on Sep 17, 2024, price target set at 44. The target of 44 remains in play, though confirmation will depend on future moves.
PCVX
BuySep 03, 2024
Target
$153.00
Current
$43.59
Performance
-60.43%
On Sep 03, 2024, PCVX was evaluated by David Risinger, who gave a Outperform rating and target of 153. Investors saw limited payoff as shares fell short of the 153 target.
HLVX
HoldJul 09, 2024
Target
$2.00
Current
$2.09
Performance
23.67%
David Risinger rated HLVX as Market Perform on Jul 09, 2024, setting a price target of 2. Despite the Hold call, shares climbed 23.67% to 2.09, revealing unexpected momentum.